Search
Pibrentasvir
go.drugbank.com/drugs/DB13878ApprovedInvestigationalMavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940]. … In combination with [DB13879], pibrentastiv is a useful therapy for patients who experienced therapeutic failure from other NS5A inhibitors.
Calcium carbimide
go.drugbank.com/drugs/DB09116ApprovedWithdrawnIts effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic product acetaldehyde. … Calcium carbimide was conceived as an alternative for the treatment of alcoholism with a reduced side effect profile either when it is consumed accompanied by alcohol or without it.
Relacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigational[A275455,L56096] By competitively blocking the glucocorticoid receptor, relacorilant prevents cortisol from activating anti-apoptotic survival pathways, thereby restoring the efficacy of cytotoxic therapies … [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089]
Pantoprazole
go.drugbank.com/drugs/DB00213ApprovedInvestigationalPantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme … is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from
Products: Nb-pantoprazoleFexinidazole
go.drugbank.com/drugs/DB12265Approved[A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021. … [A237555, L35940] It is currently marketed by Sanofi-Aventis.[L35940]
Somapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigational[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.
Miltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalIt can be administered topically or orally and is only indicated in patients aged 12 years or older.
Factor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalWhen activated by thrombin at the site of injury, the FXIII pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit. … Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical
Typhoid Vi polysaccharide vaccine
go.drugbank.com/drugs/DB10803ApprovedInvestigationalIt is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older. … The bacterial culture is inactivated in the medium with the capsular polysaccharides precipated from the solution.
Trifarotene
go.drugbank.com/drugs/DB12808ApprovedInvestigationalTrifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects as compared to older